Capivast® 200 mg (Capivasertib INN)

Targeted AKT Inhibitor for Advanced Breast Cancer

📌 Indications:

Capivast® 200 mg is indicated for the treatment of:

• Hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer

• Used in combination with Fulvestrant in patients who have progressed after endocrine therapy

• Especially beneficial in patients with:

  • PIK3CA mutation

  • AKT1 mutation

  • PTEN loss/alteration

---

Pharmacology:

Capivasertib is a selective inhibitor of AKT1, AKT2, and AKT3, which are key components of the PI3K/AKT signaling pathway responsible for tumor cell growth, survival, and resistance to endocrine therapy.
By inhibiting AKT, Capivast helps:

• Reduce tumor cell proliferation

• Promote cancer cell apoptosis

• Improve response to endocrine therapy

• Delay progression in resistant breast cancer

Dosage & Administration:

• Dose should be taken strictly according to oncologist’s prescription

• Usually administered as an oral tablet regimen with scheduled dosing cycles

• Can be taken with or without food

• Swallow tablets whole with water

• Dose modification may be required based on side effects or lab abnormalities

⚠️ Patients should not change dose or schedule without physician guidance.

---

Precautions & Warnings:

Capivasertib therapy requires careful monitoring due to potential serious adverse reactions:

• Hyperglycemia: Monitor fasting blood glucose & HbA1c

• Diarrhea: Early use of antidiarrheal treatment recommended

• Skin reactions/rash: May require topical/systemic treatment

• QT prolongation risk: Caution in cardiac patients

• Infections: Monitor for signs of infection

• Liver function: Periodic LFT monitoring advised

---

Contraindications:

• Hypersensitivity to Capivasertib or any formulation component

---

Pregnancy & Lactation:

• Not recommended during pregnancy (may cause fetal harm)

• Women of childbearing potential must use effective contraception

• Breastfeeding should be avoided during treatment and for a recommended period after last dose

---

Side Effects:

Common side effects include:

• Diarrhea

• Rash / dermatitis

• Nausea

• Fatigue

• Vomiting

• Hyperglycemia

• Decreased appetite

• Stomatitis

• Increased liver enzymes (ALT/AST)

Serious side effects may include:

• Severe skin reactions

• Severe hyperglycemia

• Serious infections

---

Storage Conditions:

• Store below 30°C

• Keep away from moisture and direct sunlight

• Keep in original packaging

• Keep out of reach of children